• Record sample volumes drive 49% revenue and 152% EBITDA growth
• Secured $200m debt facility to support accelerated PhotonAssay deployment
• Expanding partnerships with major global laboratories and miners

Chrysos Corporation Ltd (ASX:C79) ('Chrysos' or the 'Company') has delivered strong first half FY26 financial performance as the Company continues to see rapid growth in sample volume aligned with adoption of its PhotonAssay technology. Total Revenue was $43.3m, up 49% on the previous corresponding period (pcp), and EBITDA was $14.3m, a 152% increase on the pcp. EBITDA Margin improved to 33%, compared to 20% in 1H FY25. The Company signed eight new lease agreements in the half and a further six post-period, bringing the total number of contracted units to 72. This strong performance was driven by record sample volumes, with Chrysos' sales and marketing team converting more mining projects to PhotonAssay. Chrysos' balance sheet remains strong, with $72m in available funding, which will be bolstered by a new $200m committed debt facility. The Company deployed four units in the half, with a strong pipeline of contracted units supporting an acceleration of deployments in CY26. Chrysos continues to expand its relationships with major global laboratories, including a foundational partnership with Bureau Veritas in South America, and direct relationships with miners such as Newmont and Allied Gold.

Revenue range of $80m to $90m, EBITDA range of $20m to $27m for FY26.

The positive outlook for gold prices is expected to provide favourable conditions for strong revenue from assay samples into the rest of FY26. Chrysos' sales and marketing team continues to work with existing and potential customers to convert mining projects to PhotonAssay to support both new leases and drive higher volume through existing deployments.